Relative value assessment: characterizing the benefit of oncology therapies through diverse survival metrics from a US perspective

References

• Macmillan Cancer SupportCancer’s unequal burden: the reality behind improving cancer survival rates2014 Available from: http://www.macmillan.org.uk/documents/cancersunequalburden_2014.pdfAccessed November 18, 2016
   Google Scholar
• American Association for cancer researchCancer progress report2013 Available from: http://www.cancerprogressreport.orgAccessed November 18, 2016
   Google Scholar
• JagsiRSulmasyDPMoyBValue of cancer care: ethical considerations for the practicing oncologistAm Soc Clin Oncol Educ Book2014e146e14924857095
   PubMedGoogle Scholar
• AbernethyAAbrahamsEBarkerATurning the tide against cancer through sustained medical innovation: the pathway to progressClin Cancer Res20142051081108624523437
   PubMedGoogle Scholar
• EriksonCSalsbergEForteGBruinoogeSGoldsteinMFuture supply and demand for oncologists: challenges to assuring access to oncology servicesJ Oncol Pract200732798620859376
   PubMedGoogle Scholar
• de AngelisRSantMColemanMPCancer survival in Europe 1999-2007 by country and age: results of EUROCARE–5-a population-based studyLancet Oncol2014151233424314615
   PubMed Web of Science ®Google Scholar
• HostenkampGLichtenbergFRThe impact of recent chemotherapy innovation on the longevity of myeloma patients: US and international evidenceSoc Sci Med201513016217125703669
   PubMed Web of Science ®Google Scholar
• SleijferS“It’s the economy, stupid”: strategies for improved cost containment in cancer treatmentClin Pharmacol Ther201495436536724646487
   PubMedGoogle Scholar
• MariottoABYabroffKRShaoYFeuerEJBrownMLProjections of the cost of cancer care in the United States: 2010-2020J Natl Cancer Inst2011103211712821228314
   PubMed Web of Science ®Google Scholar
• OECD iLibraryHealth at a glance: Europe 20142014 Available from: 10.1787/health_glance_eur-2014-enAccessed November 18, 2016
   Google Scholar
• MillerJDFoleyKARussellMWCurrent challenges in health economic modeling of cancer therapies: a research inquiryAm Health Drug Benefits20147315316224991399
   PubMedGoogle Scholar
• SchnipperLEDavidsonNEWollinsDSAmerican Society of clinical oncology statement: a conceptual framework to assess the value of cancer treatment optionsJ Clin Oncol201533232563257726101248
   PubMed Web of Science ®Google Scholar
• SchnipperLEDavidsonNEWollinsDSUpdating the American Society of clinical oncology value framework: revisions and reflections in response to comments receivedJ Clin Oncol201634242925293427247218
   PubMed Web of Science ®Google Scholar
• ChernyNISullivanRDafniUA standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)Ann Oncol20152681547157326026162
   PubMed Web of Science ®Google Scholar
• Memorial Sloan Kettering Cancer CenterDrugAbacus2015 Available from: http://abacus.realendpoints.com/abacus-mskcc?ab-eff=1000&ab-tox=0.1&ab-nov=1&ab-rare=1&ab-pop=1&ab-dev=1&prog=1.0&ab-need=1&ab-time=1478798514Accessed November 18, 2016
   Google Scholar
• SchadendorfDHodiFSRobertCPooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanomaJ Clin Oncol201533171889189425667295
   PubMed Web of Science ®Google Scholar
• FriedmanLMFurbergCDDeMetsDLSurvival analysisFundamentals of Clinical Trials4th edNew York, NYSpringer-Verlag New York2010269291
   Google Scholar
• BrodyTClinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines2nd edOxford, UKAcademic Press2011
   Google Scholar
• KarweitJKotapatiSWagnerSShawJWWolfeSWAbernethyAPAn expanded portfolio of survival metrics for assessing anticancer agentsAm J Manag Care2017231546128141932
   PubMedGoogle Scholar
• National Cancer InstituteSurveillance, epidemiology, and end results (SEER) cancer STAT fact sheets2016 Available from: https://seer.cancer.gov/statfacts/Accessed November 18, 2016
   Google Scholar
• GuyotPAdesAEOuwensMJWeltonNJEnhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curvesBMC Med Res Methodol201212922297116
   PubMed Web of Science ®Google Scholar
• MarkitIHSLife sciences PharmOnline International (PolI) database Available from: www.ihsglobalinsight.comAccessed September 8, 2016
   Google Scholar
• SiegelRLMillerKDJemalACancer statistics, 2016CA Cancer J Clin201666173026742998
   PubMed Web of Science ®Google Scholar
• HodiFSChesneyJPavlickACCombined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trialLancet Oncol201617111558156827622997
   PubMed Web of Science ®Google Scholar
• RobertCLongGVBradyBNivolumab in previously untreated melanoma without BRAF mutationN Engl J Med2015372432033025399552
   PubMed Web of Science ®Google Scholar
• DaviesABriggsASchneiderJThe ends justify the mean: outcome measures for estimating the value of new cancer therapiesHealth Outcome Res Med201231e25e36
   Google Scholar
• JoulainFProskorovskyIAllegraCMean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancerBr J Cancer201310971735174324045663
   PubMed Web of Science ®Google Scholar
• KyteDDuffyHFletcherBSystematic evaluation of the patient-reported outcome (pro)content of clinical trial protocolsPLoS One2014910e11022925333349
   PubMedGoogle Scholar
• RobertCSchachterJLongGVPembrolizumab versus ipilimumab in advanced melanomaN Engl J Med2015372262521253225891173
   PubMed Web of Science ®Google Scholar
• BinderGMilentijevicDSquierMWhitingSBrownGRenschlerMFMagnitude of benefit and costs for recent solid tumor agentsPoster presented at: International Society for Pharmacoeconomics and Outcomes Research 19th Annual International MeetingMay 31– June 4, 2014 2014Montréal, QC, Canada
   Google Scholar
• GarrisonLPCost-effectiveness and clinical practice guidelines: have we reached a tipping point? An overviewValue Health201619551251527565265
   PubMedGoogle Scholar